Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Takeda India Leadership Amid Realignment

This article was originally published in PharmAsia News

Executive Summary

Whether or not it's a rejig in the normal course of business isn't very clear, but Japanese pharma giant Takeda has "realigned" certain teams as it pursues plans to provide sustainable access to its medicines under a new leadership in India.

You may also be interested in...



Takeda-Shire In India: Sleeping Giant?

Will Takeda take a less measured approach in India, where Shire brings it a significant on-market portfolio? Scrip outlines the current shape of things in the promising but complex emerging market as the two companies head towards combining forces globally.

Merck KGaA Exec On Innovating Vaccine Manufacturing To Tackle Outbreaks

The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.

Rivals Challenge Nintedanib In India

Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.

Topics

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel